Current Advances in Psychedelic Medicine in the Treatment of Substance Use Disorders

Distance Training Glossary | Print Version | Email This Page To A Friend

Training Details

Event Dates and Timeframe
Wednesday, November 11, 2020 at 09:00 AM until 10:00 AM
Location and Delivery Method
Delivery Method
Online / Web Delivered
Cost Range
FREE

Host And Instructor

Host
Psychiatry & Behavioral Health Learning Network
Instructor
Dr. David Smith, MD
class/provider logo image

Credits

Contact Hours: 1.00

Training Overview Description

This webinar will include a general overview of psychedelics and their current use to treat substance use disorders, and will also include a brief outline of the first, second and third wave of the psychedelic revolution.

Event-specific Details

Despite the growing evidence of their therapeutic benefit for various conditions, classifying psychedelics as a Schedule 1 drug (defined as drugs of abuse with no therapeutic benefits) has severely hampered research on their use in the treatment of Substance Use Disorders. Based on the current, various controlled studies demonstrating their effectiveness, there is a strong case to be made that rescheduling psychedelics drugs would advance therapeutic research. When incorporated thoughtfully into treatment, psychedelics have the potential to reshape biological approaches in the treatment of substance use disorders and related psychiatric conditions such as depression and post-traumatic stress disorder.

Substances to be covered in this webinar include LSD and the treatment of alcoholism, MDMA-assisted psychotherapy for severe post-traumatic stress disorder, Ketamine for refractory depression, Psilocybin (mushrooms) for the treatment of despair and hopelessness in addictive disease in death and dying patients, Ayahuasca (leaves and bark) for the treatment of opiate addiction and major depressive disorders, Ibogaine (from toad secretions) for the treatment of opioid dependence, Peyote for the treatment of alcoholism and use in Native American rituals, and medical cannabis and CBD for the treatment of pain and substance use disorder.

Upon completion of this webinar, attendees will know more about:

  • Brief history of the use of psychedelics during the first, second, and third psychedelic revolutions.
  • Understanding of the different psychedelic substances and their therapeutic effects
  • Today’s research and the barriers to that research due to their Schedule 1 classification and current antiquated attitudes towards psychedelics as effective therapy tools

About the Speaker

Dr. David Smith, MD
Founder of Haight Ashbury Free Clinic
Founder of Journal of Psychedelic Drugs (now called J. of Psychoactive Drugs)
Retired Adjunct Clinical Professor at UCSF
San Francisco, California

Dr. Smith founded the Haight Ashbury Free Clinics in 1967, during the Summer of Love, inaugurating the principle of “Health Care is a Right, not a Privilege.” He is Chair, Addiction Medicine & MQAC, for Muir Wood Adolescent and Family Services in Petaluma, California, a residential treatment center for teens with substance abuse and co-occurring disorders, the Medical Director for Avery Lane Healing Center for Women, as well as the Medical Director of Center Point, in San Rafael, California, a therapeutic community focused on those coming out of the criminal justice system. Dr. Smith is a Diplomate of the American Board of Addiction Medicine, a past President of the American Society of Addiction Medicine (ASAM) and the California Society of Addiction Medicine (CSAM). He is the Founding Editor of the Journal of Psychoactive Drugs and co-author of “Unchain Your Brain: 10 Steps to Breaking the Addictions that Steal Your Life.” He is currently working on his memoir, covering his early years, through the Summer of Love, and up to today.

Continuing Education
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME). NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NACCME designates this program for a maximum of 1.0 AMA PRA Category 1 Credit™ for physicians and 1.0 contact hour for addiction professionals, nurses, physician assistants, and psychologists.

If you are clicking the "Submit" button and nothing is happening, please ensure you've answered all the questions, have flash player downloaded, and try again.

If you continue to have issues, please clear your browser's cache, or please try to register using a different browser.
If you are still experiencing issues, please contact: mpangaro@naccme.com